Lilly

A MEDICINE COMPANY

Annual Meeting of Shareholders

MAY 4, 2026

Safe Harbor Statement

This presentation and related discussion may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based on management's current intentions and expectations. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting the company's products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; the negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access; developments or uncertainties related to our or competitive products, including as may relate to safety or efficacy concerns; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and a consolidated supply chain; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations; issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities; reliance on third-party relationships and outsourcing arrangements; the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; fluctuations in foreign currency exchange rates, changes in interest rates and inflation or deflation; significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization; litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property; changes in tax law and regulations, tax rates, or events that differ from our assumptions related to tax positions; regulatory changes, developments, and uncertainty; regulatory oversight and actions regarding the company's operations and products; regulatory compliance problems or government investigations; risks from the proliferation of counterfeit, misbranded, adulterated, diverted or illegally compounded products; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; asset impairments and restructuring charges; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements contained in this presentation and related discussion, which, except as otherwise noted, speak only as of the date of this presentation.

Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements contained in this presentation and related discussion to reflect events or circumstances after the date of this presentation.

Board of Directors

David Ricks
Chair, President and Chief Executive Officer, Eli Lilly and Company

Ralph Alvarez
Operating Partner, Advent International Corporation

Katherine Baicker, Ph.D.
Provost, University of Chicago and Professor, Harris School of Public Policy

Carolyn R. Bertozzi, Ph.D.
Professor of Chemistry, Stanford University

Erik Fyrwald
Chief Executive Officer, International Flavors & Fragrances Inc.

Mary Lynne Hedley, Ph.D.
Senior Scientific Fellow, Broad Institute of MIT and Harvard

Jamere Jackson
Chief Financial Officer, AutoZone, Inc.

Kimberly Johnson
Former Chief Operating Officer, T. Rowe Price Group, Inc.

William Kaelin Jr., M.D.
Professor of Medicine, Harvard Medical School

Juan Luciano
Chair of the Board, Chief Executive Officer and President, Archer Daniels Midland Company

Jon Moeller
Executive Chairman, The Proctor & Gamble Company

Gabrielle Sulzberger
Senior Managing Director at Centerbridge Partners, L.P.

Ernst & Young LLP

Linda Hill
Partner

Ben Labas
Partner

Agenda

1. MATTERS FOR VOTE BY SHAREHOLDERS

- Election of Four Directors
- Advisory Vote on Executive Compensation Paid to the Company’s Named Executive Officers
- Ratification of the Appointment of Ernst & Young LLP as the Independent Auditor for 2026
- Management Proposals: Amendments to Articles of Incorporation
  - *Eliminate Classified Board Structure*
  - *Eliminate Supermajority Voting Provisions*
- Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair
- Shareholder proposal to prepare an annual lobbying report

2. PRELIMINARY VOTING RESULTS

3. ADJOURNMENT

4. REPORT TO SHAREHOLDERS

5. QUESTION-AND-ANSWER FORUM

Board of Directors

Standing for Election

Carolyn R. Bertozzi, Ph.D.

Professor of Chemistry,
Stanford University

William Kaelin Jr., M.D.

Professor of Medicine,
Harvard Medical School

Jon Moeller

Executive Chairman,
The Proctor & Gamble Company

David Ricks

Chair, President and
Chief Executive Officer,
Eli Lilly and Company

Powered by Purpose



Growing Our Portfolio

Cardiometabolic Health

Mounjaro®
(global launch)

Zepbound®

Foundayo™

Oncology

Inluriyo™
(new launch)

Jaypirca®
(new indication)

Immunology

Omvoh®
(new indication)

Neuroscience

Kisunla™
(global launch)

2025 Results Highlights

$65.2B in revenue

$55B total committed to investing in M&Q since 2020

$13.3B invested in R&D

15% dividend increase

Q&A FORUM

THANK YOU